Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia

Georgios Pongas1, Swapan Kumar Dasgupta, Perumal Thiagarajan

  • 1Michael E. DeBakey Veterans Affairs Medical Center, Department of Medicine, Baylor College of Medicine, Houston, TX United States.

Thrombosis Research
|July 9, 2013
PubMed

Insights

Infections can trigger heparin-induced thrombocytopenia (HIT) by causing antibodies to form against platelet factor 4 (PF4) and lipopolysaccharide (LPS). This immune response explains spontaneous HIT in patients without prior heparin exposure.

Area of Science:

  • Immunology
  • Hematology
  • Infectious Diseases

Background:

  • Heparin-induced thrombocytopenia (HIT) is an immune condition causing low platelets and blood clots after heparin exposure.
  • Spontaneous HIT, occurring without heparin use, has been observed in infected patients, suggesting alternative triggers.
  • Platelet factor 4 (PF4) binds to lipopolysaccharide (LPS), a component of gram-negative bacteria.

Purpose of the Study:

  • To investigate the presence of anti-PF4/heparin antibodies in patients with gram-negative bacteremia.
  • To explore the immunogenicity of PF4/LPS complexes and their role in spontaneous HIT.

Main Methods:

  • Measured anti-PF4/heparin antibody titers in patients with bacteremia and healthy controls.
  • Assessed the interaction between fluorescently labeled PF4 and LPS using spectral quenching.
  • Tested cross-reactivity of HIT patient antibodies with PF4/heparin complexes.

Main Results:

  • Patients with bacteremia exhibited significantly higher anti-PF4/heparin antibody titers than controls (26.3 ± 34 units vs. 6.3 ± 2.38 units, P=0.001).
  • PF4 demonstrated concentration-dependent interaction with LPS.
  • Antibodies from HIT patients cross-reacted with PF4/heparin complexes.

Conclusions:

  • The PF4/LPS complex is immunogenic, inducing antibodies that cross-react with PF4/heparin.
  • This cross-reactivity offers an explanation for spontaneous HIT in patients never exposed to heparin.
  • These antibodies may contribute to the thrombocytopenia observed in infections.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...